We are live on
!
Find out more
Vir Biotechnology
231 hedge funds and large institutions have $2.06B invested in Vir Biotechnology in 2023 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 83 increasing their positions, 75 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
58% more call options, than puts
Call options by funds: $11M | Put options by funds: $6.98M
35% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 26
11% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 75
3% more funds holding
Funds holding: 224 → 231 (+7)
1.58% more ownership
Funds ownership: 64.66% → 66.24% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less capital invested
Capital invested by funds: $2.18B → $2.06B (-$120M)
Holders
231
Holders Change
+7
Holders Change %
+3.13%
% of All Funds
3.68%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
35
Increased
83
Reduced
75
Closed
26
Calls
$11M
Puts
$6.98M
Net Calls
+$4.06M
Net Calls Change
+$1.52M
Top Buyers
Top Sellers
| 1 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$49.6M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$28.1M |
| 3 |
Morgan Stanley
New York
|
-$14.8M |
| 4 |
Capital Fund Management (CFM)
Paris,
France
|
-$5.76M |
| 5 |
Goldman Sachs
New York
|
-$5.66M |
